Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 12/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319001 | 0.77 | CCR2 (1.00) | CCR2RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL13006179 | 0.77 | CCR2 (1.00) | CCR2RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL319610 | 0.75 | CCR2 (0.68) | CCR2RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL3487757 | 0.75 | CCR2 (0.68) | CCR2RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL3241217 | 0.75 | CCR2 (0.68) | CCR2RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL7973568 | 0.73 | CCR2 (0.66) | CCR2RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL7238858 | 0.73 | CCR2 (0.71) | CCR2RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL3954242 | 0.73 | CCR2 (0.69) | CCR2RAB9ANPC1ALDH1A1 | |
| SCHEMBL8317734 | 0.73 | CCR2 (0.69) | CCR2RAB9ANPC1ALDH1A1 | |
| SCHEMBL7973572 | 0.73 | CCR2 (0.66) | CCR2RAB9ANPC1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569562-B2 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | claimed |
| EP-1838701-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | Elan Pharmaceuticals Inc. (US) | 2007-10-03 | — | — | EP | claimed |
| US-20060270657-A1 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | claimed |
| WO-2006078753-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | claimed |
| US-7569562-B2 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1838701-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | Elan Pharmaceuticals Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20060270657-A1 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006078753-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270657-A1 | N-substituted heterocyclic sulfonamides | SULT2A1, PSEN1, PSEN2 | CCR2 1834/4885RAB9A 2447/4885NPC1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.